Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct a...

Descripción completa

Detalles Bibliográficos
Autores principales: Novembre, Elio, Tosca, Mariangela, Caffarelli, Carlo, Calvani, Mauro, Cardinale, Fabio, Castagnoli, Riccardo, Chiappini, Elena, Cravidi, Claudio, Del Giudice, Michele Miraglia, Duse, Marzia, Licari, Amelia, Manti, Sara, Martelli, Alberto, Ricci, Giampaolo, Pingitore, Giuseppe, Marseglia, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109428/
https://www.ncbi.nlm.nih.gov/pubmed/35578294
http://dx.doi.org/10.1186/s13052-022-01272-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109428/
https://www.ncbi.nlm.nih.gov/pubmed/35578294
http://dx.doi.org/10.1186/s13052-022-01272-z

Ejemplares similares